ClinicalTrials.gg

Program

SIBP-A16 injection

Its studies are mostly in Premature Birth, led by Sinopharm.

Furthest: phase 2, since Jan 5, 20262 company-led studies, 2 open or runningNext primary completion: Mar 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sinopharm22 open or runningphase 2since Jan 5, 2026Jul 30, 2025Mar 31, 2027phase 2 · NCT07363837

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 30, 2025First study: early phase 1 study in Respiratory Syncytial Virus (RSV)First studyNCT07106918 · 140 planned · China
  2. Jan 5, 2026Phase 2 study in Premature BirthPhase 2 reachedNCT07363837 · 36 planned · China

Ahead

  1. Mar 31, 2027Primary completion: phase 2 study in Premature BirthNCT07363837
  2. Apr 30, 2027Primary completion: early phase 1 study in Respiratory Syncytial Virus (RSV)NCT07106918

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07363837Premature Birth · China2Not yet recruitingMar 31, 202736
NCT07106918Respiratory Syncytial Virus (RSV) · ChinaEarly 1RecruitingApr 30, 2027140

How it is read

Names in the registry

  • “SIBP-A16 injection”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.